Proactive Investors - Run By Investors For Investors

City broker reckons Polarean shares are worth three times their current value

“The annual burden of pulmonary disease in the US is estimated to be over US$150bn and Polarean expects over US$500mln in system sales just to top-tier institutes,” read Northland’s note
lung x ray
Polarean’s drug-device platform can be added to existing MRI systems to achieve an improved level of lung function imaging

Broker Northland Capital has initiated coverage of shares in the medical devices specialist Polarean Imaging PLC (LON:POLX) with a 46p a share valuation.

The Northland target, derived using discounted cash flow analysis, is roughly triple the current price.

The company is currently running two phase III trials for its drug-device platforms, which analyst Vadim Alexandre believes will propel it into the lucrative pulmonary disease market, which is estimated to be worth US$150bn in the US alone.

“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients.

The shares were off 15% in early trade after it said it had conditionally raised US$4mln from investors at a price of 14p.

Those who took part in the fundraiser will no doubt be keenly interested in the Northland analysis, which speaks to the significant potential of Polarean, which listed on AIM in March.

View full POLX profile View Profile

Polarean Imaging PLC Timeline

Related Articles

iphone with apps
May 16 2019
The California-based telehealth company is seeking to raise $6 million to scale up its proprietary platform over the next 60 to 90 days
The "St. Noire" video game
March 24 2019
The company embraces digital interactive entertainment as well as augmented reality, virtual reality and artificial intelligence
Phone and laptop with images of people and social media graphics
May 29 2019
The company’s business-to-business social network is the fastest growing digital marketing, e-commerce platform in the cannabis industry

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use